Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies.

Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1?, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.

Abstract: A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally VH1, a CH1 region and a further variable domain nominally VH2, a light chain comprising, in sequence from the N-terminal, a variable domain nominally VL1, a CL domain and a variable domain nominally VL2, wherein said heavy and light chains are aligned to provide a first binding site formed by a first variable domain pair of VH1 and VL1 and a second binding site formed by a second variable domain pair of VH2 and VL2, wherein there is a disulfide bond between a variable domain pair forming a binding site, and said fusion protein is conjugated to a PEG polymer.

Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognizes an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from anti-body-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein.

Abstract: The present invention provides a homogeneous assay for identifying an antibody producing cell producing an antibody which binds to a selected antigen comprising: a) providing a population of antibody producing cells; b) incubating said population of antibody producing cells with a selected antigen and a labeled anti-antibody antibody, wherein said anti-antibody antibody is capable of distinguishing cells producing an antibody which binds to the selected antigen from those cells which do not; and c) identifying an antibody producing cell capable of producing an antibody which binds to the selected antigen.

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to a method of obtaining an antibody with a desired function, the method comprising: a) bringing a population of B cells into contact with a capturing agent; b) separating the captured B cells from the uncaptured B cells; c) culturing a plurality of captured B cells wherein said B cells have not been sorted into single B cells immediately prior to culturing; d) screening a plurality of the cultured cells to identify cells capable of producing an antibody with the desired function; and e) obtaining the desired antibody therefrom.

Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.